ABT Stock Analysis — Abbott Laboratories
Sector: Healthcare
AI Verdict
At 15.8x forward earnings for 54.5% growth, this is cheap for a diversified healthcare name with entrenched diagnostics, but execution risk is real after a -33.43% year.
Competitive Moat
Abbott's moat comes from its diversified portfolio of medical devices, diagnostics, and branded generic drugs, which creates cross-segment resilience and entrenched hospital relationships. Its proprietary diagnostic platforms and global distribution network make it difficult for competitors to displace its core products.
Summary
Abbott is notable right now for a 54.5% expected jump in earnings next year, with the stock trading at just 15.8x forward earnings.
Where It Stands
Shares are down -33.43% over the past year, the RSI sits at a neutral 50.8, and the forward P/E of 15.8x is well below the healthcare sector median of 22x.
Key Metrics
- RSI: 50.8 — Neutral
- Trailing P/E: 24.4x
- Forward P/E: 15.8x
- PEG Ratio: 0.45
- Earnings Growth: +0.5%
- Revenue Growth: +0.1%
- Market Cap: $152.3B
- Dividend Yield: 0.03%
- 1-Year Return: -33.43%
- 52-Week High: $139.06
- 52-Week Low: $81.97
Analyst Consensus
25 Buy · 10 Hold · 0 Sell (35 analysts)
Bull Case
You’re paying 15.8x next year’s earnings for 54.5% forward EPS growth, which is cheap for the growth on offer if Abbott’s diagnostics and device franchises keep delivering.
Bear Case
If the forward P/E reverts to the sector median of 22x, there’s upside, but if execution slips and the P/E falls to 12x (the energy sector median), the stock could see another 24% downside from here.
Catalyst to Watch
Watch for upcoming earnings and product launch updates — any sign that the 54.5% EPS growth target is at risk would undermine the current valuation.